Please assess the completion status of the following clinical trial:

Trial Title: Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Cytologically confirmed relapsed CNS lymphoma~  * Arising from primary CNS lymphoma or systemic non-Hodgkin's lymphoma~* Evidence of brain parenchymal involvement, cerebrospinal fluid (CSF) involvement, or ocular involvement after radiation treatment or intrathecal chemotherapy~* Tumors must be CD20+ on pathologic analysis~* Refractory or persistent disease allowed~* No complete obstruction of the CSF pathway within the ventricular system unless alleviated by external beam radiotherapy or systemic chemotherapy~* No obstructive hydrocephalus~PATIENT CHARACTERISTICS:~* Karnofsky performance status \> 50%~* Must have an Ommaya reservoir~* Granulocyte count \> 1,500/mm\^3~* Platelet count \> 50,000/mm\^3~* Anticipated survival ≥ 1 month~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Recovered from toxicity of prior therapy~* Prior intrathecal methotrexate, cytarabine, or thiotepa for CNS lymphoma allowed~* Concurrent systemic chemotherapy for treatment of disease outside meninges allowed except for high-dose methotrexate, high-dose cytarabine, high-dose thiotepa, or investigational agents~* No history of whole-brain or craniospinal radiation \< 1 week before study entry~* No history of intrathecal chemotherapy \< 1 week before study entry~* No concurrent intrathecal chemotherapy

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- intrathecal rituximab (Type: EXPERIMENTAL): 3 dose levels of intrathecal rituximab, 10mg, 25mg, 50mg

Based on this trial design, predict the completion outcome and termination type (if applicable).